Q-omics provides the consensus-scored MIR4717 profile across patient tissues and cancer cell-line models. MIR4717 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MIR4717 is differentially expressed in 3, with the highest sampling consensus in LUAD. Additionally, MIR4717 RNA expression shows 4,485 significant pathway-activity associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, and LUAD as cancer lineages where MIR4717 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR4717 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR4717 survival associations across molecular data types. MIR4717 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR4717 RNA expression–survival associations across cancer types. High MIR4717 expression shows unfavorable associations in KIRC, THYM, BRCA, CHOL, HNSC and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MIR4717 RNA expression.
This table summarizes MIR4717 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR4717. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR4717 shows lower tumor expression in LUAD, LUSC and THCA. The LUAD box plot shows higher MIR4717 RNA expression in normal versus tumor tissue (log2 FC = −1.410, t-test p < 0.001).
This table shows molecular features associated with MIR4717 in patient tissues and cancer cell lines. In patient samples, MIR4717 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set.
